Your shopping cart is currently empty

HSD17B13-IN-31 (compound 32) serves as a highly effective inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM and less than 1 μM when using estradiol and Leukotriene B3 as substrates, respectively. This compound is critical in managing nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | HSD17B13-IN-31 (compound 32) serves as a highly effective inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM and less than 1 μM when using estradiol and Leukotriene B3 as substrates, respectively. This compound is critical in managing nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1]. |
| Molecular Weight | 465.35 |
| Formula | C21H18Cl2N2O4S |
| Cas No. | 2758802-33-2 |
| Smiles | N(C(=O)C1=CC(Cl)=C(O)C(Cl)=C1)C2=C(C(NCCC3=C(OC)C=CC=C3)=O)SC=C2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.